• Commercial rollout progressing across three U.S. foundation customers
• SAPPHIRE Study preparing to commence with contracting and ethics processes underway
• Salix® Coronary Flow module nearing FDA submission

Artrya Limited (ASX: AYA), a medical technology company commercialising its Salix® AI-powered cloud platform for the assessment and management of coronary artery disease, released its Appendix 4C - Quarterly Cashflow Report and Activities Update for the quarter ended 31 March 2026. The company's commercial rollout progressed across its three U.S. foundation customers - Tanner Health, Northeast Georgia Health System (NGHS), and Cone Health. Tanner Health has fully integrated the Salix® Coronary Anatomy platform and Salix® Coronary Plaque module across all five hospitals, with Salix® live in clinical practice. Integration work is also advancing at NGHS and Cone Health, with go-live expected by the start of FY27. Artrya secured the final two participants for its upcoming U.S. multi-centre SAPPHIRE Study, which will evaluate the prognostic and clinical utility of Salix® Plaque Analysis. The preparation for FDA submission of the Salix® Coronary Flow module is in its final stages, with the module demonstrating strong accuracy in performance. Artrya also strengthened its U.S. leadership with the appointment of an experienced General Manager, U.S. Operations, and Dr. Jeffrey Le Benger as a U.S.-based director. The company reported a pro forma cash position of $76.6M at 31 March 2026.

Artrya did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.

Artrya's commercial focus in the coming quarter will be on expanding revenue at Tanner Health by increasing weekly volumes of Salix® Plaque assessments, while also prioritizing the completion of integrations at NGHS and Cone Health to have all three customers live and generating Salix® Coronary Anatomy and Plaque revenues from the start of the 2027 financial year.